The Compound Investor
  • Stocks
  • ETFs
  • Portfolio
  • Dividend Millionaires
  • Archive
  • Contact
  • Mutual Funds & ETFs

    VYMI: International Blue Chip Dividend ETF; Still Reasonable Long-Term Value

    by The Compound Investor April 21, 2021
    April 21, 2021

    It has been just under a year since the Vanguard International High Dividend Yield ETF (VYMI) first featured here. Remember this is basically a sister to domestic-focused VYM – the Vanguard High Dividend Yield ETF – which I’m sure many readers will know quite well. Despite its name suggesting otherwise,…

  • StocksConsumer Defensive

    Molson Coors: Looking To Turn The Corner With Dividends Resuming In 2021

    by The Compound Investor April 16, 2021
    April 16, 2021

    As regular readers will know, Molson Coors (TAP) had its issues even before COVID hit. In very broad terms I think you can boil those down to two points. Firstly, the company took on a bunch of debt to buy out the rest of the MillerCoors JV in 2016. Debt…

  • StocksFinancial

    Toronto Dominion: Set For A Good 2021, But A Return To Pre-COVID Performance Now Reflected In The Share Price

    by The Compound Investor April 8, 2021
    April 8, 2021

    A year ago it might have been tough to imagine Toronto Dominion (TD) putting down the kind of financial results it has of late. The economic environment was obviously pretty darn scary back then, with the early economic data resembling nothing ever seen before. The potentially devastating impact to bank…

  • Portfolio

    Portfolio: Q1 2021 Review

    by The Compound Investor April 3, 2021
    April 3, 2021

    It really doesn’t feel like three months have passed since the last portfolio update. Domestic stocks largely continued where they left off, with the S&P 500 gaining another 6.2% inclusive of dividends in Q1. That came amid a $1.9t stimulus package and the ramping up of vaccine programs across the…

  • StocksHealthcare

    Johnson & Johnson: Dividend Aristocrat At A Fair Price For Long-Term Investors

    by The Compound Investor March 30, 2021
    March 30, 2021

    Although it comes under a single ticker, Johnson & Johnson (JNJ) is more akin to a giant one-stop healthcare shop. Folks likely know the consumer division thanks to brands like Listerine, Neutrogena and Tylenol. Its pharmaceutical segment sells patented drugs across a range of areas – oncology, immunology, neurology, infectious…

Load More Posts

Subscribe via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Article Calendar

April 2021
M T W T F S S
 1234
567891011
12131415161718
19202122232425
2627282930  
« Mar    

Subscribe via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Post Calendar

April 2021
M T W T F S S
 1234
567891011
12131415161718
19202122232425
2627282930  
« Mar    

Recent Articles

  • VYMI: International Blue Chip Dividend ETF; Still Reasonable Long-Term Value April 21, 2021
  • Molson Coors: Looking To Turn The Corner With Dividends Resuming In 2021 April 16, 2021
  • Toronto Dominion: Set For A Good 2021, But A Return To Pre-COVID Performance Now Reflected In The Share Price April 8, 2021
  • Privacy Policy
  • Contact
  • About

©2021 thecompoundinvestor.com - All Right Reserved.


Back To Top
  • Stocks
  • ETFs
  • Portfolio
  • Dividend Millionaires
  • Archive
  • Contact